Local infusion of FGF-saporin reduces intimai hyperplasia

Journal of Surgical Research

Volumn 60, Issue 2, 1996, Pages 339-344

  Mattar, Samer G ^a   Hanson, Stephen R ^b   Pierce, Glenn F ^a   Chen, Changyi ^a   Hughes, John D ^a   Cook, Jennifer E ^a   Shen, Chun ^a   Noe, Beverly A ^a   Suwyn, Carolyn R ^a   Scott, J Ryland ^a   Lumsden, Alan B ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Prizm Pharmaceuticals Inc   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BROXURIDINE; POLITEF; RECOMBINANT PROTEIN; RIBOSOME INACTIVATING PROTEIN; SAPORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; CAROTID ENDARTERECTOMY; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; CELL DIVISION; DOGS; EPIDERMAL GROWTH FACTOR; HYPERPLASIA; IMMUNOTOXINS; MALE; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH, VASCULAR; N-GLYCOSYL HYDROLASES; PLANT PROTEINS; RECOMBINANT PROTEINS;

EID: 0030024792     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0054     Document Type: Article

References (21)

1. Castellot, J. J., Cochran, D. L., and Karnovsky, M. J. Effect of heparin on vascular smooth muscle cells. 1. Cell metabolism. J. Cell. Physiol. 124: 21, 1985.
2. Reidy, M. A., Fingerle, J., and Lindner, V. Factors controlling the development of arterial lesions after injury. Circulation 86 [Suppl. III]: III43, 1992.
3. Epstein, S. E., Speir, E., and Finkel, T. Do antisense approaches to the problem of restenosis make sense? Circulation 88: 1351, 1993.
4. Lappi, D. A., Martineau, D., and Baird, A. Biological and chemical characterization of basic FGF-saporin mitotoxin. Biochem. Biophys. Res. Commun. 160: 917, 1989.
5. Lappi, D. A., Maher, P. A., Martineau, D., and Baird, A. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor. J. Cell. Physiol. 147: 17, 1989.
6. Beitz, J. G., Davol, P., Clark, J. W., Kato, J., Medina, M., Frackelton, A. R., Lappi, D. A., Baird, A., and Calabresi, P. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo. Cancer. Res. 52: 227, 1992.
7. Lappi, D. A., Ying, W., Barthelemy, I., Martineau, D., Prieto, I., Benatti, L., Soria, M., and Baird, A. Expression and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J. Biol. Chem. 269: 12552, 1994.
8. Scott, N. A., Nunes, G. L., King, S. B., Harker, L. A., and Hanson, S. R. Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation 90: 1951, 1994.
9. McDonald, J. R., Ong, M., Shen, C., Sosnowski, B. A., Caton, M., Tetzke, T., Cook, J. E., and Parandoosh, Z. Large Scale Purification and Thorough Characterization of E. Coli Expressed Basic Fibroblast Growth Factor-Saporin Mitotoxin. FASEB J. 9: 410, 1995.
10. Lappi, D. A., Ying, W., Barthelemy, I., Martineau, D., Prieto, I., Benatti, L., Soria, M., and Baird, A. Expression and activity of a recombinant basic fibroblast growth factor-saporin fusion protein. J. Biol. Chem. 269(17): 12552, 1994.
11. Cook, J., Beitz, J., Davol, P., Parandoosh, Z., Lykstad, K., Mohler, M. In vivo characterization of a novel mitotoxin, bFGF-SAP; Pharmacokinetics, metabolism, and efficacy in the mouse tumor xenograft model. Pharm. Res. 11: 79, 1994. [Abstract]
12. Moscatelli, D. Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine endothelial cells. J. Cell. Biol. 107: 753, 1988.
13. Casscells, W., Lappi, D. A., Olwin, B. B., Wai, C., Siegman, M., Speir, E. H., Sasse, J., and Baird, A. Elimination of smooth muscle cells in experimental restenosis: Targeting of fibroblast growth factor receptors. Proc. Natl. Acad. Sci. USA 89: 7159, 1992.
14. Berridge, M. J. Inositol triphosphate and calcium signalling. Nature (London) 361: 315, 1993.
15. Ohno, T., Gordon, D., San, H., Pompili, V. J., Imperiale, M. J., Nabel, G. J., and Nabel, E. G. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265: 781, 1993.
16. Lynch, C. M., Clowes, M. M., Osborne, W. R., Clowes, A. W., and Miller, A. D. Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: A model for gene therapy. Proc. Natl. Acad. Sci. USA 89: 1138, 1992.
17. Simons, M., Edelman, E. R., DeKeyser, J., Langer, R., and Rosenberg, R. D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359: 67, 1992.
18. Morishita, R., Gibbons, G. H., Ellison, K. E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T., and Dzau, V. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA 90: 8474, 1993.
19. Burgess, T. L., Fisher, E. F., Ross, S. L., Bready, J. V., Qian, Y., Bayewitch, L. A., Cohen, A. M., Herrera, C. J., Hu, S. S. F., Kramer, T. B., Lott, F. D., Martin, F. H., Pierce, G. F., Simonet, L., and Farrell, C. L. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA 92(9), 4051, 1995.
20. Stirpe, F., Gasperi-Campani, A., Barbieri, L., Falasca, A., Abbondaza, A., and Stevens, W. A. Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwart), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree). Biochem. J. 216: 617, 1983.
21. Lumsden, A. B., Kelly, D., Dodson, T. F., Kotze, H., Hanson, S. R., and Harker, L. A. Interruption of implanted vascular graft thrombosis by brief local treatment with D-Phe-Pro-Arg chloromethylketone. Circulation 82(Suppl.) 603, 1990.